Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (51)

2024

  1. Explainable machine learning on baseline MRI predicts multiple sclerosis trajectory descriptors

    PLoS ONE, Vol. 19, Núm. 7 JULY

  2. Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients

    Frontiers in Pharmacology, Vol. 15

2023

  1. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

  2. Genomic Factors and Therapeutic Approaches in HIV-Associated Neurocognitive Disorders: A Comprehensive Review

    International journal of molecular sciences, Vol. 24, Núm. 18

  3. MiRNA Differences Related to Treatment-Resistant Schizophrenia

    International Journal of Molecular Sciences, Vol. 24, Núm. 3

  4. Protein Plasma Levels of the IGF Signalling System Are Altered in Major Depressive Disorder

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  5. Results of a focused cardiac ultrasound program conducted by neurologists within a stroke care network with cardiac imaging units

    Revista Espanola de Cardiologia, Vol. 76, Núm. 2, pp. 103-111

2022

  1. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  3. Expert-Agreed Practical Recommendations on the Use of Cladribine

    Neurology and Therapy

2021

  1. Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  2. Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology

    Frontiers in Neurology, Vol. 12

  3. Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter

    Neurologia, Vol. 36, Núm. 5, pp. 346-352

  4. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement

    Neurologia, Vol. 36, Núm. 1, pp. 50-60

  5. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials

    Expert Review of Neurotherapeutics, Vol. 21, Núm. 7, pp. 755-778

  6. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports

    Expert Review of Neurotherapeutics, Vol. 21, Núm. 5, pp. 547-558

  7. Temporal trends in the incidence and prevalence of Multiple Sclerosis in the Northwest of Spain

    Multiple Sclerosis and Related Disorders, Vol. 52

  8. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)

    Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406

  9. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)

    Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442

2020

  1. Epidemiology of multiple sclerosis in Santiago de Compostela (Spain)

    Acta Neurologica Scandinavica, Vol. 142, Núm. 3, pp. 267-274